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Abstract
Background: Dystonia is a movement disorder with high heterogeneity regarding phenotypic appearance and etiology that occurs in both sporadic and familial
forms. The etiology of the disease remains unknown. However, there is increasing evidence suggesting that a small number of gene alterations may lead to dystonia.
Although pathogenic variants to the familial type of dystonia have been extensively reviewed and discussed, relatively little is known about the contribution of single-
nucleotide polymorphisms (SNPs) to dystonia. This review focuses on the potential role of SNPs and other variants in dystonia susceptibility.
Methods: We searched the PubMed database for peer-reviewed articles published in English, from its inception through January 2018, that concerned human
studies of dystonia and genetic variants. The following search terms were included: ‘‘dystonia’’ in combination with the following terms: 1) ‘‘polymorphisms’’ and 2)
‘‘SNPs’’ as free words.
Results: A total of 43 published studies regarding TOR1A, BDNF, DRD5, APOE, ARSG, NALC, OR4X2, COL4A1, TH, DDC, DBH, MAO, COMT, DAT, GCH1,
PRKRA, MR-1, SGCE, ATP1A3, TAF1, THAP1, GNAL, DRD2, HLA-DRB, CBS, MTHFR, and MS genes, were included in the current review.
Discussion: To date, a few variants, which are possibly involved in several molecular pathways, have been related to dystonia. Large cohort studies are needed to
determine robust associations between variants and dystonia with adjustment for other potential cofounders, in order to elucidate the pathogenic mechanisms of
dystonia and the net effect of the genes.
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Introduction
Dystonia is a movement disorder with high heterogeneity regarding
phenotypic appearance and etiology.1 The prevalence of dystonia is
estimated to be 16:100,000.2,3 In 2013, a new general definition and
classification of dystonia were introduced by an international panel of
dystonia experts.4 The two main axes of this classification are considered
to be the etiology and the clinical features.4 However, the pathophysio-
logy and cause of most dystonia cases remain largely unknown.5
A polymorphism is a variation in the DNA sequence that occurs in a
population with a frequency of 1 % or higher.6,7 When a variation
occurs in a single nucleotide, at a specific position in the genome, it is
called an SNP (single-nucleotide polymorphism).8,9 SNPs can occur
within coding sequences of genes, non-coding sequences, introns,
or the regions between genes (also known as intergenic regions).10,11
An SNP across a coding sequence of a gene can be characterized as
synonymous (when the protein sequence is not affected) and non-
synonymous (when the amino acid sequence of the protein is altered).10,12
The non-synonymous SNPs are divided into missense (when they result in
a different amino acid) and nonsense (when they result in a premature
stop codon).10,12 Recently, it has been recommended that both terms,
‘‘mutation’’ and ‘‘polymorphism’’, be replaced by the term ‘‘variant’’.13,14
An additional modifier (e.g. pathogenic, benign) to the term ‘‘variant’’
should be used, in order for its pathogenic or benign effect to be
declared.13,14
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The importance of genetic factors was unambiguously demonstrated
with the identification of causative pathogenic variants in monogenic
cases of familial dystonia under the autosomal dominant, autosomal
recessive, or X-linked mode of inheritance.3 Furthermore, a few
candidate gene association studies (CGASs) have suggested that the
presence of specific genetic loci may confer susceptibility to dystonia.15
Genetic variations may affect dystonia’s phenotypic appearance, age at
onset, and spread to adjacent body regions, and may also affect the
penetrance of other pathogenic variants suspected for dystonia.15
Previous reviews have mainly discussed the genetics of dystonia in
general its monogenic forms and its phenotypic divergence.3,16–25
However, genetics of sporadic forms of dystonia with no clearly
discernible family history, and results from case–control studies are
relatively rarely discussed.15,18,25 Therefore, in the present review article,
we discuss the current state of knowledge regarding genetics of dystonia,
by emphasizing the CGASs that have linked single nucleotide poly-
morphisms and variants across genes that predispose to dystonia. Owing
to the lack of a widely accepted nomenclature gene classification system
for dystonia, we have used gene names for loci identification.26 The main
aim of the current comprehensive review is to shed some light on which
polymorphisms predispose for dystonia, and to what extent.
Methods: study identification and selection
In order for any potentially relevant study to be identified, we
searched through the Pubmed database (https://www.ncbi.nlm.nih.
gov/pubmed) for peer-reviewed articles published in English, from its
inception to January 2018, that concerned human studies of dystonia and
genetic polymorphisms. The following search terms were included:
‘‘dystonia’’ in combination with 1) ‘‘polymorphisms’’ and 2) ‘‘SNPs’’ as
free words. The complete search algorithm is available in the S1
Appendix. The last literature search was performed on February 20,
2018. Additionally, reference lists of retrieved articles were examined in
order to identify missing from the initial database search results. The
flowchart presenting the selection procedure of the studies is presented in
Figure 1. Published studies between 1996 and 2017 were included.
The following data were extracted from each study, when possible:
author, year of publication, ethnicity of the studied population,
numbers of cases and controls, age at disease onset, mean age and
gender distribution, tested variants, family history of the participants,
screening or not for the TOR1A GAG pathogenic variant, correction
for multiple comparisons, assessment of Hardy–Weinberg equilibrium,
and the tested dystonia phenotypes.
Results and discussion
Published studies between August 2001 and September 2017 were
included. Baseline characteristics from studies regarding TOR1A,
BDNF, DRD5, APOE, ARSG, NALC, OR4X2, COL4A1, TH, DDC,
DBH, MAO, COMT, DAT, GCH1, PRKRA, MR-1, SGCE, ATP1A3,
TAF1, THAP1, GNAL, DRD2, HLA-DRB, CBS, MTHFR, and MS
are presented in Supplementary Tables 1–5. GnomAD frequencies
(http://gnomad.broadinstitute.org/) and the type of individual variants
are available at the S2 Appendix.
TOR1A
The TOR1A gene is a five-exon gene that covers an 11-kb region in
chromosome 9. The TOR1A protein, called TorsinA, belongs to the
family of the AAA+ ATPases. It can be found in the endoplasmic
reticulum and the nuclear envelope of most cells,8 including those of
the central nervous system.18 The function of TorsinA and how
TOR1A gene pathogenic variants lead to dystonia remains largely
unknown.27 TorsinA acts mainly as a molecular chaperone.28 The
molecular and cellular processes in which TorsinA is involved include
the interactions between cytoskeleton and membrane, important
functions of the endoplasmic reticulum and the nuclear envelope,
and the regulation of cellular lipid metabolism.18,29–31 It is
known that TorsinA needs to bind to TOR1AIP2 (Torsin 1A
Interacting Protein 2) or to Heat Shock Protein Family A (Hsp70)
Member 8 (HSPA8) in order to be activated,32 a procedure that
is impaired by the GAG deletion, as has been confirmed by
crystallography.33,34
TOR1A remains the most extensively studied gene in both mono-
genic and sporadic forms of dystonia.15 However, results from case–
control studies yielded conflicting results, with the association being
affected by body distribution, ethnicity, and other phenotypic
manifestations. A number of case–control studies have been conducted
so far35–52 and quite a few TOR1A variants have also been investigated
(rs1801968, rs2296793, rs1182, rs3842225, rs13283584, rs11787741,
rs13297609, rs2287367, rs1043186, and rs35153737). Apart from
case–control studies, a number of variants have been identified through
mutational screening (rs766483672, rs80358233, rs75881350, rs1183,
rs563498119, rs573629050, rs1045441, rs144572721).53 Additionally,
three meta-analyses have been conducted so far examining the effects of
TOR1A gene variants on dystonia.15,39,40 The most recent evidence
stemming from a meta-analysis, reveals a significant association of the
rs1182 (allele frequency [AF]50.1666) and the rs1801968 (AF50.1236
for the G allele and AF54.061e-6 for the C allele) TOR1A variants with
the development of focal dystonia (FD) and writer’s cramp (WC)
respectively.15 Moreover, variants within 39-UTR (untranslated region)
encoded by exon 5 represent an additional functional genetic locus of
TOR1A, though it may be under synergistic action with other TOR1A
genetic variants.15 This comes in accordance with a recent case–control
study, suggesting an association of the rs35153737 in the 39-UTR of
TOR1A with dystonia; a result, though, that has been attributed to
functional variants that are in high linkage disequilibrium (LD).52
From a functional aspect, loci containing the aforementioned
variants appear to have consequences; variants across exon 4 and 39-
UTR encoded by exon 5, in particular, appear to overall influence the
function of the TOR1A gene.15 More specifically, rs1801968 was
confirmed to be associated with reduced penetrance of the GAG
pathogenic variant in humans.54,55 Regarding the 39-UTR of exon 5,
there is only some indication that specific variants across this region
may have some functional consequences under synergistic action.15,52
Interestingly, based on the results regarding frequencies, computa-
tional analyses and function experiments, rs563498119 in the 39-UTR
of TOR1A was reported to change the expression of the TOR1A gene.53
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The regulation of TOR1A expression, by mutating the conserved
region of the binding site of the human microRNA (hsa-miR-494),
where rs563498119 is located, hints towards hsa-miR-494 being a
possible therapeutic target.53
BDNF and APOE
Among the major mechanisms in dystonia, the reduced inhibition
of the motor system and the increased plasticity are included.56 In
greater detail, increased plasticity in the hand representation area
of the motor cortex has been observed in focal hand dystonia,
blepharospasm (BSP), and cervical dystonia (CD) using high-resolution
transcranial stimulation.57 Consequently, abnormal plasticity within
certain motor cortical circuits may represent a lineament of adult-onset
dystonia forms.57,58
Synaptic plasticity is influenced by the brain-derived neurotrophic
factor (BDNF). A common SNP across the BDNF gene within the
prodomain region is the rs6265 (G/A) (AF50.1896) and it results in
the substitution of Val in amino acid position 66 with Met (ValRMet),
which may influence synaptic plasticity59–61 and is possibly involved in
dystonia development. Healthy carriers of the val66met appear to have
differences in brain structure and abnormal motor cortex plasticity
as well.62,63 Rs6265 has been found to be associated with quite a
few diseases such as Parkinson’s disease, Alzheimer disease (AD),
schizophrenia, bipolar disease, depressive disorder, and panic dis-
orders, although strong evidence has yet to be presented.64–69
The studies that have been conducted so far regarding the role of
the rs6265 on dystonia have yielded conflicting results. More precisely,
rs6265 has been reported to be associated with CD and BSP in
Figure 1. Flow chart presenting the selection of the studies included in the current review.
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multiethnic and Chinese cohorts respectively.70,71 Additionally, higher
frequency of bilateral postural arm tremor in CD patients with the
BDNF Met66Met variant than inVal66Met and Val66Val carriers has
also been observed.72 However, these results have not been replicated
in Serbian, Chinese, Italian, or Caucasian dystonia cohorts.58,73–75 To
date, two meta-analyses have evaluated the effects of rs6265 variant on
dystonia.75,76 The most recent reports a statistically significant overall
effect of the AA genotype on the development of idiopathic dystonia.76
However, the lack of reproducibility of the positive results could be
attributed, among others, to the culture of null hypothesis significance
testing,77 the possible influence of epigenetic mechanisms in the gene
function (such as DNA methylation),78 and to the fact that additional
variants across the BDNF may regulate the level of serum BDNF and
its function.79 BDNF could be considered a potential therapeutic target
in dystonia, as in neurological and psychiatric disorders.80–82
Apolipoprotein E is the product of the APOE gene, which connects
to lipids in order to form lipoproteins. There are at least three alleles
(e2, e3, and e4) of the APOE gene, with the commonest one being the
e3. The main function of lipoproteins is to package cholesterol and
other fats, and transport them throughout tissues including the central
nervous system.83 The e4 allele is associated with an increased risk of
AD compared with the e3 allele, whereas the e2 allele is associated
with decreased risk.84 Like BDNF, APOE may also influence neural
plasticity and remodeling.71,85 In a Japanese cohort, E4 carriers were
shown to develop dystonia on average approximately 10 years earlier
than e4 non-carriers.58 TorsinA is also involved in cellular lipid
metabolism.29 Therefore, variants that influence lipid biology may
contribute to dystonia. Matsumoto et al.85 suggested that the e4 allele
may severely affect neuronal reorganization and this impairment of
neuronal repair may contribute to an earlier age of dystonia onset.
Consequently, it is possible that variants within TOR1A, BDNF, APOE
or even other genes under synergistic action, influence the phenotypic
manifestation of dystonia.
THAP 1
Around a hundred missense, nonsense, and frameshift pathogenic
variants, throughout most part of the coding region of the ‘‘thanatos
associated protein domain containing, apoptosis associated protein 1’’
(THAP1) gene, have been associated with dystonia3,86,87 in a gene-
tically diverse population.18 The THAP1 gene encodes the transcrip-
tion factor THAP1, a zinc finger protein with an amino-terminal
THAP domain, a proline-rich region, and a carboxy-terminal nuclear
domain as well.88 THAP1 is thought to regulate the transcription of
several key genes, TOR1A included.18,89
Case–control studies regarding THAP1 variants are limited35,40
because of the variety and the rarity of THAP1 variants. Therefore,
most findings derive from mutational screening and the comparison
between dystonia cases and healthy individuals.86,87,90–96 However,
there is an indication that the frequency of the C allele of the
c.71+126T.C pathogenic variant was elevated in British dystonia
patients.90 -237_236GA.TT was also over-represented in dystonia
when compared with controls in a European cohort94 but these results
could not be replicated.90,91,97 Furthermore, the IVS2-87 A.G
(rs11989331, AF50.003428) was over-represented in dystonia in an
Indian study.95 The MAF of rs200209986 was also found to be
significantly higher in dystonic patients (MAF50.359%) than in the
controls (MAF50.0318%, p,0.05) in the Vemula et al.96 study and
the 1000 Genomes project (MAF50.0916%, p,0.05), but not when
compared with the EVS database (MAF50.199%, p50.13).
The large amount of THAP1 pathogenic variants linked to dystonia
may suggest an interplay between environmental and genetic factors.98
Further, the type of work or the exposure to environmental factors,
such as pesticides, may possibly predispose to dystonia development in
pathogenic variant carriers.21,86,87
GNAL, TAF1, GCH1, MR-1 (PNKD), SGCE, ATP1A3, PRKRA,
HLA-DRB, CBS, MTHFR, and MS
GNAL (guanine nucleotide-binding protein subunit alpha L) has
been identified as responsible for adult-onset dystonia, which is pri-
marily cervical or cranial.99 A few GNAL variants (rs9303742,
rs9675415, rs1895689, rs8095592, rs72865259, rs1647556, rs200508915,
rs138151459, rs2071140, rs2071141, rs199571902) have been examined
for association with generalized, multifocal, segmental, and focal
dystonia.100 Despite the fact that no strong evidence for association with
dystonia was found, novel variants are constantly reported in single
dystonia patients with various phenotypes,100 leading to approximately 30
different GNAL variants in dystonia patients.3 GNAL encodes guanine
nucleotide-binding protein G subunit alpha [Ga(olf)]. Ga(olf)is involved in
both the direct and indirect pathway to the activation of adenylate
cyclase, by coupling dopamine type 1 receptors and the adenosine A2A
receptors in medium spiny neurons, respectively.99 In fact, the
involvement in the indirect pathway of the activation leads to
the activation of adenylyl cyclase type 5 (AC5). AC5 is encoded by
the adenylyl cyclase 5 (ADCY5) gene, which was recently reported to
be a co-founder of dystonia.101 It is possible that epistasis pheno-
menon with ADCY5 influences the causative effect of GNAL variants.
Newman at al.40 in 2012, apart from TOR1A and THAP1, which are
described in the above sections, genotyped several variants of other
genes as well (TAF1, GCH1, MR-1 (PNKD), SGCE, ATP1A3, and
PRKRA).40 The results were negative regarding quite a few variants
across TAF1, MR-1 (PNKD), SGCE, ATP1A3, and PRKRA, yet weak
associations were observed for the rs12147422 (AF50.217), rs3759664
(AF50.2353), and rs10483639 (AF50.2539) of GCH1 (GTP cyclohy-
drolase 1) variants when the entire, non-homogeneous phenotypic,
dystonia group was compared with controls. The lack of reproduci-
bility of these associations could be explained by the low prevalence of
dystonia, suggesting the need of collaborative studies.102 Nevertheless,
GCH1 belongs to the confirmed causative genes of dopa-responsive
dystonia. Additionally, the penetrance of GCH1 pathogenic variants
appears to be considerably higher in females than in males.103 The
GCH1 gene encodes the rate-limiting enzyme in the biosynthesis of
dopamine via the biopterin pathway. GTP cyclohydrolase1 is involved
in tetrahydrobiopterin neo-synthesis from GTP, as it catalyzes the first
step of this reaction.18 Variants of GHC1 influence enzyme activity,
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leading to a deficiency in dopamine and serotonin.104 Therefore,
a possible role of GCH1 in non-monogenic forms of dystonia should
not be dismissed, as scientific reasoning could not be substituted by
statistical analysis.105
Finally there is no strong evidence for the association between HLA-
DRB variants or variants in the homocysteine pathway (cystathionine
b-synthase [CBS], methionine tetrahydrofolate reductase [MTHFR],
methionine synthase [MS] genes) with dystonia.50
Dopamine pathway genes (DAT1, DRD1, DRD2, DRD3, DRD4,
DRD5, COMT, DAT, TH, MAO-A and -B, DDC, and DBH)
Dystonic movements are considered the result of impaired function
and abnormalities of dopaminergic neurotransmission and signaling
in the basal ganglia.106 The involvement of the dopaminergic system
in the pathophysiology of dystonia has also been enhanced via the
mutated genes of the dopamine pathway in monogenic forms of
dystonia (GCH1).107 Allele 2 of the DRD5 has been associated with
increased risk of CD and BSP in British cohorts.108,109 Allele 6 and
allele 4 of the DRD5 have been associated with CD in British and
Italian cohorts respectively,109,110 thus strongly supporting the invol-
vement of the DRD5 gene in dystonia.111 However, DRD5 has not
been associated with dystonia in Italian, US, and German studies.49,50
Dopamine receptor genes regulate neurotransmission in response to
dopamine.112 Dopamine receptors are divided into two families, based
on either the activation (D1-like receptors: DRD1 and DRD5) or the
inhibition (D2-like receptors: DRD2, DRD3, and DRD4) of adenylate
cyclase.113 Although the negative results in genes of dopamine
signaling pathway (dopamine receptors) are few,49,114,115 Groen
et al.115 suggested that changes in dopamine levels may be secondary
during the dystonia course and that rare single nucleotide variants of
dopamine genes are possibly associated with dystonia.116
ARSG, NALC, OR4X2, COL4A1
To date, only two genome-wide association studies (GWASs) have
been performed in order to identify variants that may predispose to
dystonia.117,118 According to their results, there is a preliminary indi-
cation that arylsulfatase G (ARSG) and sodium leak channel (NALCN)
variants play that role.117,118
In a GWAS executed by Lohmann et al.,117 it was suggested that the
intronic rs11655081 (AF50.181) of the ARSG gene was associated with
musician’s dystonia and writer’s cramp. The missense rs61999318
(AF50.002619) was significantly higher in the group of writer’s cramp
patients than in European Americans in the EVS database (p5
0.0013).119 Functional analysis suggested that rs61999318 may repre-
sent a functional variant, as the underlying amino acid substitution
of isoleucine at position 493 with threonine (p.I493T) appears to
be disease causing.119 ARSG is the protein encoded by ARSG; it
hydrolyzes sulfate esters and is therefore implicated in cell signaling,
synthesis of hormones, and protein degradation.120 Moreover, it may
be involved in neuronal ceroid lipofuscinosis,121 which can present
itself as dystonia.117 In view of the former considerations, ARSG could
be targeted as a gene for further study mainly in task-specific dystonias.
According to the GWAS from Mok et al.,118 the cluster of variants
near exon 1 of NALCN was found nearest to the significance threshold
in a British population with CD. The most statistically significant
variants were NALCN (rs61973742, rs1338051, rs9518385, rs9518384,
rs1338041 rs3916908), COL4A1 (rs619152), RGL1 (rs12132318), OR4X2 3
(rs67863238), intergenic (rs1249277, rs1249281, rs9416795), KIAA1715
(rs10930717), OR4B1 (rs35875350).118 However, a replication of this
GWAS case–control study did not report any association of NALCN,
OR4X2, COL4A1, and intergenic variants,122 and the results for
NALC (rs1338041, rs61973742) were also not reproduced in a
Chinese population.123 NALCN is a voltage-independent and cation-
non-selective channel. Its main function is the leaky sodium transport
across neuronal membranes and the regulation of neuronal excit-
ability.124 In general, variants in genes, whose protein also acts like an ion
channel, are crucial components and may be additional factors for
dystonia development.117 ANO3 is among the confirmed genes that cause
a monogenic form of late-onset craniocervical dystonia, with a possible
effect on the calcium-activated chloride channel.3,125
Concluding remarks
Genetic factors confer susceptibility to dystonia development. More
precisely, based on our review, exon 4 and the 39-UTR of exon 5
represent loci that appear to have a strong influence on the function of
the TOR1A gene, and their pathogenic variants may be associated with
sporadic forms of dystonia, specifically with focal distribution.
Moreover, rs6265 of BDNF appears to be strongly associated with
dystonia as well. As the function of the BDNF gene may be influenced
by other variants, additional loci across it may be worth examining.
Further analysis of the ARSG gene, notably the rs61999318 in focal
task-specific dystonia cohorts and the DRD5 gene in focal dystonia, is
warranted. Additional studies of GCH1 may be required. Owing to
their rarity, THAP1 gene variants are insecure targets for future case–
control studies. The continuing identification of pathogenic variants
that cause monogenic forms of dystonia will lead us to new possible
targets for case–control studies.1,3
Next-generation sequencing has led to the identification of new
dystonia genes on a monthly basis.3,125,126 Therefore, a large amount
of common and rare genetic variants that may predispose to dystonia
have been identified. Also, a few identified variants may affect
penetrance, age at onset, spread to adjacent body, or the phenotype of
dystonia.15 However, it is not prudent to assume that all these genes
truly lead to dystonia, and therefore results need to be interpreted with
caution. Therefore, applying the CGASs approach to next-generation
data could possibly shed some light on the mechanisms of the complex
traits.127
The understanding of the genetic basis of monogenic and sporadic
forms of dystonia will permit the identification and deeper knowledge
of dystonia’s pathogenesis. This will provide physicians with more
personalized tools to manage dystonia in the future, even from the time
of diagnosis, and they may also be used for assessing the biological
progression of the disease and guide the treatment decisions.128
Implications, even at the DNA and/or RNA level, are already
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considered as new possible targeted therapeutic approaches.53,80
The stronger grasp on dystonia’s genetic susceptibility will also
improve genetic testing and counseling.
The lack of validation reproducibility of the positive results could
be attributed to several factors; firstly, the culture of null hypothesis
significance testing.77 Moreover, low power CGASs because of
relatively small sample sizes is a common phenomenon, as the
effective population should ideally be very large (,10,000 individuals)
in order for a modest genetic effect to be identified.129 The interplay
between environmental (e.g. pesticides)86,98 and genetic factors, as well
as among genetic factors,1 may variably determine the penetrance of
pathogenic variants and the phenotype.18,20,86,98,130,131 Furthermore,
the phenotypic divergence of dystonia and the possible classification
bias should be considered, as the majority of the studies were
performed before the new dystonia classification.4,15 Finally, epigenetic
mechanisms may represent an additional explanation for the lack of
result validation.78
Therefore, it is of great necessity that more collaborative
studies132,133 with adjustment for other potential cofounders (e.g.
gene–environment interactions with adjustment for pesticide expo-
sure,86 air pollution,134 diseases of the anterior segment of the eye,
preceded injury, trauma, surgical intervention or sore throat,130 time
spent handwriting per day and the writing time before dystonia
onset,135 genome methylation status) and a supportive functional
analysis be conducted in the future. In this way, the pathogenic
mechanisms of dystonia and the net effect of the genes could be
elucidated and, consequently, the inherent limitations of association
studies will be avoided.136
Certain limitations of the present review need to be acknowledged.
Firstly, supportive data regarding functional analysis of variants would
give more robustness to our conclusions. Moreover, we included
relevant studies regardless of the sample power and without any prior
quality assessment. Therefore, a possible confounding by population
stratification or technical factors cannot totally be excluded. Finally,
based on our search strategy procedure, it is possible that some eligible
studies might not have been identified. However, this is an inherent
limitation of such studies, and the inclusion of a large number of
studies does not affect the major conclusions of our results.
We should bear in mind that positive results from genetic association
studies require biological and functional evidence that the risk variant
is actually involved in the pathophysiology and the pathogenesis of the
relevant disease. Pathway-based analysis could facilitate more robust
analysis even of GWAS and provide additional biological insights
on the mechanisms of disease complex traits.137,138 Therefore, the
scientific reasoning could not be replaced by any single statistical value,
index, or test.105,139 As a consequence, by the correct interpretation of
statistical values, the misinterpretation of results could be avoided.140
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